Granules India’s Net Profit surges by 26% to Rs. 41 Cr.

2026-08-12 11:51:03 Business

943

Hyderabad, October 25, 2016: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced today financial results for its second quarter ended 30th September, 2016.

Consolidated Q2FY17 Financial Results Highlights:-

? Revenue: Rs. 364 Cr., an increase of 3% compared to Rs. 353 Cr. in Q2FY16

? EBITDA: Rs. 78 Cr., an increase of 12% compared to Rs. 69 Cr. in Q2FY16

? Operating Margin improved by 179 basis point to 21.5% from 19.7% in Q2FY16

? Net Profit: Rs. 41 Cr., an increase of 26% compared to Rs. 32 Cr. in Q2FY16

? Net Profit Margin improved by 208 basis point to 11.2% from 9.1% in Q2FY16

The Company?s standalone sales during the quarter were Rs. 341 Cr. In this quarter the Company recorded EBITDA and PAT of Rs. 75 Cr. and Rs. 33 Cr. respectively.

The Company?s Board of Directors has approved interim dividend of 20 paise per share of face value of Rs. 1 each.

?We are focused to achieve our long term goals as we move ahead in the investment phase. Our API and PFI capacity enhancements within our base business and Greenfield API facility in Vizag are both on track. In addition, our product development and subsequent filling continues to make steady progress. During the quarter, the U.S. FDA approved our ANDA for Ibuprofen 200 mg orange tablets which enhances our product portfolio. We are also happy to see an increasing share of revenue coming from our formulation division which focuses on the U.S., European and Canadian markets.\" said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director.

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)
Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company?s global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.
The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.